An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma

Biochemical and Biophysical Research Communications

Volumn 426, Issue 3, 2012, Pages 363-368

  Abraham, Jinu ^a   Chua, Ying Xuan ^b   Glover, Jason M ^a   Tyner, Jeffrey W ^c   Loriaux, Marc M ^c   Kilcoyne, Aoife ^b,d   Giles, Francis J ^d   Nelon, Laura D ^b   Carew, Jennifer S ^d   Ouyang, Yongjian ^b   Michalek, Joel E ^b   Pal, Ranadip ^e   Druker, Brian J ^c   Rubin, Brian P ^f   Keller, Charles ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

^e Department of Electrical and Computer Engineering   (United States)

^f TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Imatinib; Pdgfra; Receptor tyrosine kinase; Sorafenib

Indexed keywords

IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; RAF PROTEIN; SORAFENIB;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DISEASE COURSE; ENZYME PHOSPHORYLATION; EVENT FREE SURVIVAL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; PRIMARY CELL CULTURE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; BENZENESULFONATES; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; MICE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; RAF KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RHABDOMYOSARCOMA, ALVEOLAR; SRC-FAMILY KINASES; TUMOR CELLS, CULTURED;

MURINAE;

EID: 84866931907     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.08.092     Document Type: Article

References (31)

1. Cen L., Arnoczky K.J., Hsieh F.C., Lin H.J., Qualman S.J., Yu S., Xiang H., Lin J. Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Mod. Pathol. 2007, 20:936-946.
2. Breneman J.C., Lyden E., Pappo A.S., Link M.P., Anderson J.R., Parham D.M., Qualman S.J., Wharam M.D., Donaldson S.S., Maurer H.M., Meyer W.H., Baker K.S., Paidas C.N., Crist W.M. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma - a report from the Intergroup Rhabdomyosarcoma Study IV. J. Clin. Oncol. 2003, 21:78-84.
3. Williams B.A., Williams K.M., Doyle J., Stephens D., Greenberg M., Malkin D., Pappo A.S. Metastatic rhabdomyosarcoma: a retrospective review of patients treated at the hospital for sick children between 1989 and 1999. J. Pediatr. Hematol. Oncol. 1999, 26(2004):243-247.
4. Sorensen P.H., Lynch J.C., Qualman S.J., Tirabosco R., Lim J.F., Maurer H.M., Bridge J.A., Crist W.M., Triche T.J., Barr F.G. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J. Clin. Oncol. 2002, 20:2672-2679.
5. E. Taniguchi, K. Nishijo, A.T. McCleish, J.E. Michalek, M.H. Grayson, A.J. Infante, H.E. Abboud, R.D. Legallo, S.J. Qualman, B.P. Rubin, C. Keller, PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma, Oncogene 27 (2008) 6550-6560.
6. Nishijo K., Chen Q.R., Zhang L., McCleish A.T., Rodriguez A., Cho M.J., Prajapati S.I., Gelfond J.A., Chisholm G.B., Michalek J.E., Aronow B.J., Barr F.G., Randall R.L., Ladanyi M., Qualman S.J., Rubin B.P., LeGallo R.D., Wang C., Khan J., Keller C. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res. 2009, 69:2902-2911.
7. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., Faraoni R., Floyd M., Hunt J.P., Lockhart D.J., Milanov Z.V., Morrison M.J., Pallares G., Patel H.K., Pritchard S., Wodicka L.M., Zarrinkar P.P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
8. Santos F.P., Ravandi F. Advances in treatment of chronic myelogenous leukemia - new treatment options with tyrosine kinase inhibitors. Leuk. Lymphoma 2009, 50(Suppl 2):16-26.
9. Debiec-Rychter M., Cools J., Dumez H., Sciot R., Stul M., Mentens N., Vranckx H., Wasag B., Prenen H., Roesel J., Hagemeijer A., Van Oosterom A., Marynen P. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005, 128:270-279.
10. Abraham J., Prajapati S.I., Nishijo K., Schaffer B.S., Taniguchi E., Kilcoyne A., McCleish A.T., Nelon L.D., Giles F.G., Efstratiadis A., LeGallo R.D., Nowak B.M., Rubin B.P., Malempati S., Keller C. Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Mol. Cancer Ther. 2011, 10:697-707.
11. Tallquist M.D., Soriano P. Cell autonomous requirement for PDGFRalpha in populations of cranial and cardiac neural crest cells. Development 2003, 130:507-518.
12. Lei H., Kazlauskas A. Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells. J. Biol. Chem. 2009, 284:6329-6336.
13. Amanchy R., Zhong J., Hong R., Kim J.H., Gucek M., Cole R.N., Molina H., Pandey A. Identification of c-Src tyrosine kinase substrates in platelet-derived growth factor receptor signaling. Mol. Oncol. 2009, 3:439-450.
14. Arndt C.A., Crist W.M. Common musculoskeletal tumors of childhood and adolescence. N. Engl. J. Med. 1999, 341:342-352.
15. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 21:21.
16. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D., Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002, 347:472-480.
17. van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S., Martens M., Webb A., Sciot R., Van Glabbeke M., Silberman S., Nielsen O.S. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421-1423.
18. Heinrich M.C., Corless C.L., Blanke C.D., Demetri G.D., Joensuu H., Roberts P.J., Eisenberg B.L., von Mehren M., Fletcher C.D., Sandau K., McDougall K., Ou W.B., Chen C.J., Fletcher J.A. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 2006, 24:4764-4774.
19. Liegl B., Kepten I., Le C., Zhu M., Demetri G.D., Heinrich M.C., Fletcher C.D., Corless C.L., Fletcher J.A. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J. Pathol. 2008, 216:64-74.
20. Antonescu C.R., Besmer P., Guo T., Arkun K., Hom G., Koryotowski B., Leversha M.A., Jeffrey P.D., Desantis D., Singer S., Brennan M.F., Maki R.G., DeMatteo R.P. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer Res. 2005, 11:4182-4190.
21. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
22. Donato N.J., Wu J.Y., Stapley J., Lin H., Arlinghaus R., Aggarwal B.B., Shishodia S., Albitar M., Hayes K., Kantarjian H., Talpaz M. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004, 64:672-677.
23. Wu J., Meng F., Kong L.Y., Peng Z., Ying Y., Bornmann W.G., Darnay B.G., Lamothe B., Sun H., Talpaz M., Donato N.J. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J. Natl. Cancer Inst. 2008, 100:926-939.
24. Miranda C., Nucifora M., Molinari F., Conca E., Anania M.C., Bordoni A., Saletti P., Mazzucchelli L., Pilotti S., Pierotti M.A., Tamborini E., Greco A., Frattini M. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin. Cancer Res. 2012, 18:1769-1776.
25. Keir S.T., Maris J.M., Lock R., Kolb E.A., Gorlick R., Carol H., Morton C.L., Reynolds C.P., Kang M.H., Watkins A., Houghton P.J., Smith M.A. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr. Blood Cancer 2010, 55:1126-1133.
26. Inaba H., Rubnitz J.E., Coustan-Smith E., Li L., Furmanski B.D., Mascara G.P., Heym K.M., Christensen R., Onciu M., Shurtleff S.A., Pounds S.B., Pui C.H., Ribeiro R.C., Campana D., Baker S.D. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J. Clin. Oncol. 2011, 29:3293-3300.
27. Agarwal S., Sane R., Ohlfest J.R., Elmquist W.F. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J. Pharmacol. Exp. Ther. 2011, 336:223-233.
28. Oda Y., Kohashi K., Yamamoto H., Tamiya S., Kohno K., Kuwano M., Iwamoto Y., Tajiri T., Taguchi T., Tsuneyoshi M. Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma. Cancer Sci. 2008, 99:726-732.
29. O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., Adrian L.T., Zhou T., Huang W.S., Xu Q., Metcalf C.A., Tyner J.W., Loriaux M.M., Corbin A.S., Wardwell S., Ning Y., Keats J.A., Wang Y., Sundaramoorthi R., Thomas M., Zhou D., Snodgrass J., Commodore L., Sawyer T.K., Dalgarno D.C., Deininger M.W., Druker B.J., Clackson T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
30. MacPartlin M., Smith A.M., Druker B.J., Honigberg L.A., Deininger M.W. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia 2008, 22:1354-1360.
31. Tian G., Cory M., Smith A.A., Knight W.B. Structural determinants for potent, selective dual site inhibition of human pp 60c-src by 4-anilinoquinazolines. Biochemistry 2001, 40:7084-7091.